Verve Therapeutics stock nearly doubled Tuesday after Eli Lilly agreed to buy the gene-editing company for up to $1.3 billion ...

In today's Pharmalittle roundup, we're reading about a Lilly deal, a gene therapy shock for Duchenne families, and more.

If finalized, the deal, which was also signed on to by the District of Columbia and U.S. territories, would pay out over the next 15 years. Also: Eli Lilly's experimental weight loss drug, a new Lupus ...